Weekly Analysts’ Ratings Changes for Pfizer (PFE)

Several analysts have recently updated their ratings and price targets for Pfizer (NYSE: PFE):

• 2/4/2026 – Pfizer had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $27.00 price target on the stock.
• 1/27/2026 – Pfizer had its price target raised by analysts at Cantor Fitzgerald from $24.00 to $27.00. They now have a “neutral” rating on the stock.
• 1/26/2026 – Pfizer was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 1/22/2026 – Pfizer had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/6/2026 – Pfizer is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $25.00 price target on the stock.
• 12/30/2025 – Pfizer had its “hold” rating reaffirmed by analysts at TD Cowen.
• 12/17/2025 – Pfizer had its “buy” rating reaffirmed by analysts at Guggenheim.
• 12/17/2025 – Pfizer was given a new $24.00 price target on by analysts at Wolfe Research. They now have an “underperform” rating on the stock.
• 12/15/2025 – Pfizer had its price target lowered by analysts at Bank of America Corporation from $29.00 to $28.00. They now have a “neutral” rating on the stock.
• 12/12/2025 – Pfizer had its price target lowered by analysts at Morgan Stanley from $32.00 to $28.00. They now have an “equal weight” rating on the stock.
• 12/10/2025 – Pfizer had its “outperform” rating reaffirmed by analysts at BMO Capital Markets.
• 12/10/2025 – Pfizer had its “buy” rating reaffirmed by analysts at HSBC Holdings plc. They now have a $29.00 price target on the stock.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is 126.47%.

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.